Overview

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Status:
Terminated

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

This study explores the potential to improve the quality of response obtained after induction treatment in Chronic Lymphocytic Leukemia (CLL), by giving a short and intense consolidation schema using high-dose rituximab. Patients in suboptimal response (Minimal Residual Disease persistence) after induction will be selected, as well as those who have a Minimal Residual Disease (MRD) relapse after having achieved MRD negativity.

Phase:

Phase 2

Details

Lead Sponsor:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Treatments:

Rituximab